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ABSTRACT
Eukaryotic mRNAs with premature translation-
termination codons (PTCs) are recognized and elim-
inated by nonsense-mediated mRNA decay (NMD).
NMD substrates can be degraded by different routes
that all require phosphorylated UPF1 (P-UPF1) as
a starting point. The endonuclease SMG6, which
cleaves mRNA near the PTC, is one of the three
known NMD factors thought to be recruited to non-
sense mRNAs via an interaction with P-UPF1, leading
to eventual mRNA degradation. By artificial tether-
ing of SMG6 and mutants thereof to a reporter mRNA
combined with knockdowns of various NMD factors,
we demonstrate that besides its endonucleolytic ac-
tivity, SMG6 also requires UPF1 and SMG1 to reduce
reporter mRNA levels. Using in vivo and in vitro ap-
proaches, we further document that SMG6 and the
unique stalk region of the UPF1 helicase domain,
along with a contribution from the SQ domain, form a
novel interaction and we also show that this region of
the UPF1 helicase domain is critical for SMG6 func-
tion and NMD. Our results show that this interaction
is required for NMD and for the capability of tethered
SMG6 to degrade its bound RNA, suggesting that it
contributes to the intricate regulation of UPF1 and
SMG6 enzymatic activities.
INTRODUCTION
In order to guarantee the accuracy of gene expression, eu-
karyotic cells have evolved numerous intricate quality con-
trol mechanisms. One of the best studied of these mech-
anisms is the nonsense-mediated mRNA decay pathway
(NMD) that was archetypically known as a pathway act-
ing to selectively identify and degrade mRNAs containing a
premature translation-termination codon (PTC), and hence
reduces the accumulation of potentially toxic truncated pro-
teins. However, NMD also targets various physiological
mRNAs, signifying a role for NMD in post-transcriptional
gene expression regulation in eukaryotes (1–3). Therefore,
NMD probably controls a large and diverse inventory of
transcripts which reflects the important influence of NMD
on the metabolism of the cell and consequently in many
human diseases (4,5). In order to develop pharmacological
reagents and to better understand the influence of NMDon
disease, it is essential to unravel the molecular mechanisms
that underpin NMD.
A plausible current model of NMD in human cells pos-
tulates that the decision of whether the pathway is to be
initiated relies upon competition between up-frame shift 1
(UPF1), a core NMD factor that exhibits 5′-3′ helicase and
nucleic acid-dependent adenosine triphosphatase (ATPase)
activities (6), and cytoplasmic poly-A binding protein for
binding to eukaryotic release factor 3 (eRF3) on the ter-
minating ribosome (7–11). Suppressor with morphogenetic
effect on genitalia protein 1 (SMG1), which is a phos-
phatidylinositol 3-kinase-related protein kinase (PIKK)
(12), is also recruited by ribosomes terminating translation
prematurely through interactions with the eRF1/3 and this
complex of UPF1, SMG1 and the eRF1/3 is termed the
SURF complex (13). In the presence of UPF2 and UPF3,
most likely bound to downstream exon junction complexes
(EJCs) on the mRNA, SMG1 phosphorylates UPF1 (13–
15) creating an N-terminal binding platform for SMG6 and
a C-terminal binding site for the SMG5–SMG7 complex,
the latter of which has been reported to recruit mRNA de-
cay factors (16,17) and these interactions at the N and C-
termini ofUPF1 are essential forNMD(18). SMG5, SMG6
and SMG7 each contain a 14-3-3-like domain, which in the
case of SMG6 and SMG7 has been experimentally con-
firmed to bind phosphorylated residues of UPF1 (18,19).
SMG6 can also associate with the mRNA surveillance
complex through its ability to directly bind the EJC via
conserved motifs called EJC binding motifs (EBMs) (20).
SMG5 and SMG6 both contain a C-terminal PIN (PilT N-
terminus) domain adopting a similar overall fold related to
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ribonucleases of the RNase H family but only SMG6 har-
bors the canonical triad of aspartic acid residues crucial for
nuclease activity (21–23). Thereafter, SMG6was revealed to
be the endonuclease in human andDrosophila melanogaster
cells that cleaves nonsense mRNAs in the vicinity of the
PTC (24,25).
However, less is known about the actual mRNA degra-
dation aspect of NMD but an emerging consensus is that
phosphorylated UPF1 (P-UPF1) is the common starting
point for all of the multiple decay routes that have been re-
ported to be possible in NMD (26). SMG6 is one of the
several proteins that are able to interact with P-UPF1 to ul-
timately induce RNA decay.
So far, it is not known if and how the endonuclease ac-
tivity of SMG6 is regulated so that it is used only when and
where it is needed and how this regulation would be orches-
trated. Similarly, it is not clear exactly how SMG6 achieves
target specificity; how exactly it is recruited to target mR-
NAs. In this study, we have investigated what is required
for SMG6-mediated endonucleolytic cleavage of mRNA.
Through in vivo functional assays, protein–protein interac-
tion studies and in vitro experiments, we found that SMG6
activity specifically requires SMG1 and UPF1. However,
this requirement is not dependent on the previously docu-
mented interaction between SMG6 and UPF1 phosphory-
lated at threonine 28 (18) but rather due to a newly identified
phosphorylation-independent interaction between SMG6
and the unique stalk region in the UPF1 helicase domain,
along with a contribution from the proximal portion of the
SQ domain. We confirm that this interaction is critical for
NMD and give insight into how this novel interaction may
contribute to the regulation of UPF1 and SMG6.
MATERIALS AND METHODS
Plasmids
A comprehensive description of the plasmids used and
made in this study can be found in the Supplementary Data
section.
Tethered function and NMD assays
Cells were seeded into 6-well plates and DNA co-
transfections were carried out using Lipofectamine 2000
(Life Technologies) according to the manufacturer’s
guidelines. In all tethered function assays (TFAs), 100-ng
pEGFP-C3, 100-ng pc-globin6MS2 and 2-g pCMV-
SMG6-MS2-HA or 1-g pCMV-LacZ-MS2-HA or
1-g pCMV-HA-MS2-LacZ, along with either 400-ng
pSUPuro scrambled plasmid (control) or 400-ng pSUPuro
plasmid expressing an shRNA targeting specific NMD
factors, was used. In Figure 1D, 2-g pCMV-SMG6-
MS2-HA, 1-g pCMV-SMG6m14-3-3-MS2-HA and
pCMV-SMG6mEBM-MS2-HA and 4 g of pCMV-
SMG6mPIN-MS2-HA were used. In Figure 2B–D, 400 ng
of pSUPuro plasmids expressing shRNAs against SMG1,
SMG5, SMG7, UPF1 or UPF2 were co-transfected.
In Figure 3A–C, 600 ng of RNAi-resistant (RNAiR)
pcDNA3-Flag-SMG1 or 550-ng RNAiR pcDNA3-
HA-UPF1 plasmids were also co-transfected and the
amount of DNA in each co-transformation mixture was
made equal by the addition of the corresponding empty
plasmid. In the NMD assays, 100 ng of each plasmid
producing mini- or -globin reporters containing a PTC
as well as the wild-type counterpart, 100-ng pmCMV-
rGPx1-TGC, along with either 400-ng pSUPuro control
plasmid or 400 ng of plasmids expressing two shRNA
targets against UPF1, were co-transfected. In Figure
7A, 550-ng RNAiR pcDNA3-HA-UPF1 wild-type, 600-
ng RNAiR pcDNA3-HA-UPF1Stalk and 500-ng of
RNAiR pcDNA3-HA-UPF11C were included in the
co-transformation mixtures of both the NMD rescue
experiments and the TFA rescue experiments. The shRNA
target sequence for SMG5 was defined in (27) and the rest
have been described elsewhere (28). The remainder of the
pSUPuro-based knockdown procedure, cell harvesting for
both protein and RNA samples (which were taken from the
same sample), total RNA extraction and measurement of
relative mRNA levels by quantitative reverse transcription
polymerase chain reaction (RT-qPCR) was done as pre-
viously explained (29). qPCR assays have been described
elsewhere (27,28), except for the TaqMan assay to measure
eukaryotic green fluorescent protein (eGFP) mRNA levels
that is comprised of 5′-TGAGCAAAGACCCCAACGA-
3′, 5′-GGCGGCGGTCACGAA-3′ and 5′-FAM-
GCGGATCACATGGTCCTGCTGG-BHQ1 -3′. For the
assays in Figures 3 and 6, total RNA was extracted using
the Total RNAMiniprep Kit (Sigma-Aldrich). To examine
protein levels from the assays, generally 35 000 whole cell
equivalents were separated using 6–12% sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
and the proteins were transferred to a polyvinylidene
difluoride (PVDF) membrane (Westran Clear Signal,
GE Healthcare) and probed with the indicated primary
antibodies and appropriate fluorophore-coupled secondary
antibodies. Fluorescent signals were captured using the
Odyssey Infrared Imaging System (LI-COR Biosciences).
A full inventory of all the antibodies used in this study can
be found in the Supplementary data.
Yeast two-hybrid -galactosidase plate assays
Two hundred and fifty nanograms of the desig-
nated pGADT7 and pGBKT7 plasmids were co-
transformed into Mav99 cells (31) according to the
high-efficiency LiOAc/single-stranded carrier DNA
(Clontech)/polyethylene glycol ((Clontech)/PEG) method
of transformation (32). Four co-transformants from each
co-transformation reaction were spread in equal con-
centrated patches on fresh selective plates and incubated
at 30◦C for 3 days. Thereafter, non-lethal X-gal/-
galactosidase plate assays were performed (33). Briefly,
the plates were then flooded with chloroform, completely
immersing the colonies. After 5 min, the chloroform was
decanted and the plates were inverted and dried for 5 min.
Each plate was then overlaid with 1% low melting agarose
(Promega, V2111) containing 1-mg ml−1 X-Gal and
100-mM KPO4, pH 7.0 cooled to 42◦C. Once the agarose
was hardened, the plates were inverted and incubated
at 30◦C for 24 h and then at 4◦C for 24 h before being
photographed.
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Figure 1. The SMG6 PIN domain is necessary but not sufficient for the degradation of reporter mRNA. (A) Schematic of the SMG6-tethered function
assay (TFA). (B) SMG6-TFA. HeLa cells were transfected with pc-globin-6-MS2bs, pEGFP (serving as a co-transfection control) and with plasmids
expressing each of the indicated factors fused to anMS2-HAmoiety or HA-SMG6 that lacks the MS2 moiety. RT-qPCR analysis was used to evaluate the
-globin mRNA levels, normalized to GFP mRNA levels and with mRNA levels in cells expressing the LacZ-MS2-HA set as 100. The bars represent the
mean of>6 independent experiments. Error bars indicate standard deviations (SD) andP-values are displayed in Supplementary Figure S1A.Western blots
showing the expression of the MS2-HA fusion proteins (below left blot) and that of HA-SMG6 protein (below right blot). The antibody used is indicated
at the right of each blot. * indicates unspecific bands detected using the anti-MS2 antibody. (C) Illustration of the human SMG6 protein annotated with
the mutants used in this study and the specification of each mutant. (D) As in (B), except performed using plasmids expressing SMG6-MS2-HA and the
indicated mutants thereof. Western blot displaying the expression of the specified SMG6-MS2-HA fusion proteins. (E) As in (B), except performed with
plasmids expressing the designated MS2-HA fusion proteins, where the SMG6 PIN domain (AA 1239-1419 of SMG6) fused to the MS2 coat protein
is simply denoted as PIN and its endonucleolytically inactive counterpart as mPIN. Western blot documenting the expression of the indicated MS2-HA
fusion proteins.
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Figure 2. SMG6-mediated mRNA decay requires SMG1 and UPF1. (A) Western blots examining the knockdown efficiencies of various NMD factors
from samples corresponding to the experiments shown in (B–D). Lanes 1–3 represent a serial dilution (100, 33 and 11%) of cell lysate from untransfected
HeLa cells (plain cells). Lanes 4 and 5 show the protein levels from cells expressing a control shRNA (Ctr KD) and the shRNA targeting the designated
NMD factor (KD), respectively. The detected protein is denoted at the right of each blot. (B–D) SMG-TFA as in Figure 1B, using plasmids expressing
SMG6-MS2-HA in (B), SMG6m14-3-3-MS2-HA in (C) and SMG6mEBM-MS2-HA in (D), except performed in cells depleted of various NMD factors,
whereby a plasmid expressing either a control shRNA or an shRNA targeting one of the indicated NMD factors was also included in the co-transfection
mixture. -globin reporter mRNA levels have been normalized to GFP mRNA levels and with mRNA levels in cells expressing LacZ-MS2-HA set as 100
(not shown for clarity). The bar charts depict the relative mRNA levels under control knockdown conditions (black bars) and the designated knockdown
conditions (named below each gray bar). The bars represent the mean of >6 independent experiments. Error bars indicate SD and P-values are displayed
in Supplementary Figure S1B.
Recombinant protein production
The recombinant proteins were produced in HEK293T
cells by transfecting pEFh SBP-eGFP, pEF Flag-HA-SBP-
SMG6, pSR myc-SBP-UPF1, pEFh SBP-UPF1 (codon
optimized) and derivatives thereof and following a purifi-
cation procedure formerly described (34), except that the
proteins were eluted in 1x HBS-EP+ buffer (GEHealthcare
BR-1008-26).
In vitro protein-binding experiments
For in vitro protein-binding assays, 3 × 107 of 293T
cell extracts transfected with pEF Flag-HA-SBP-SMG6 or
pEF Flag-HA-maltose-binding protein (MBP) were lysed
in NF buffer [20-mM Tris HCl (pH 7.5), 150-mM NaCl,
0.25-M sucrose, 1% Triton X-100, 0.5% Tween 20, 1-mM
dithiothreitol (DTT), 1 x protease inhibitor (Nacalai), 1
x phosphatase inhibitor (Nacalai)] containing 50-g/ml
RNase A and incubated with 0.5 mg of anti-HA-tag mAb-
Magnetic beads (TANA2, MBL) for 2 h at 4◦C. The beads
were washed by NF buffer and separated into 5–6 tubes.
The separated beads were incubated with 1000 nM of SBP-
eGFP, or SBP-UPF1 and derivatives in T buffer [20-mM
HEPES-KOH (pH 7.5), 150-mM NaCl, 2.5-mM MgCl2
and 0.05% Tween 20] complemented with 1-mMMgCl2, 1-
mM MnCl2, 1-M ZnCl2, 1-mM DTT and 0.01% bovine
serum albumin. After an incubation of 4 h, the beads were
washed four times with T buffer containing 1-mM DTT.
The bound proteins were eluted with SDS sample buffer
lacking reducing agents. After addition of reducing agents
and heat denaturation, the eluted proteins were separated
by SDS-PAGE, transferred to a membrane and probed us-
ing antibodies stipulated in the Supplementary data section.
The bands were detected using either an ECL western blot-
ting detection kit (GE Biotech) or Luminata forte (Milli-
pore) using a Lumino-Imager, LAS-4000 and Science Lab
2001 Image Gauge software (FujiPhoto Film).
In vitro RNA–protein interaction studies using MicroScale
Thermophoresis
TheMicroScale Thermophoresis (MST) assays were set up,
performed and analyzed as previously outlined (35–38).
Specifically, the 5′-labeled Cy5 RNA U30 oligonucleotide
was purchased from Microsynth.ch and diluted to 40 nM
using 1 x HBS-EP+ buffer. The solution of each desig-
nated unlabeled recombinant protein (see recombinant pro-
tein production) was serially diluted from a concentration
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Figure 3. UPF1 phospho-site mutants still rescue SMG6 activity in UPF1-depleted cells. (A) SMG6 TFA as in Figure 1B using the labeled SMG-MS2-HA
and the designated LacZ control plasmids, except a plasmid either expressing a control shRNA (black bars), an shRNA targeting SMG1 (gray bars) or a
plasmid expressing an shRNA targeting SMG1 and a plasmid expressing an RNAi resistant (RNAiR) SMG1 (green bars) have also been transfected. -
globinmRNA levels, normalized toGFPmRNA levels andwithmRNA levels in cells expressing LacZ-MS2-HAunder no knockdown, SMG1 knockdown
and SMG1 rescue conditions set as 100. The bars represent the mean of three independent experiments. Error bars indicate SD and P-values are presented
in Supplementary Figure S1C. Western blot showing SMG1 levels. Lanes 1–3 represent a serial dilution (100, 33 and 11%) of cell lysate from untransfected
HeLa cells. Lane 4 represents control shRNA (Ctr) and lane 5 represents the samples expressing the shRNA targeting SMG1. Lane 6 represents the samples
expressing the shRNA targeting SMG1 and the exogenous expression of RNAiR full-length SMG1. The detected protein is indicated on the right of the
blot. (B) SMG6-TFA performed exactly as in (A), except endogenous UPF1 levels were knocked down via expression of two shRNAs targeting UPF1
and complemented using exogenously expressed RNAiR UPF1 wild-type (red bars). (C) SMG6-TFA executed as in (B), except plasmids exogenously
expressing RNAiR UPF1-T28A (pink bars), -S1096A (brown bars) and -T28A/S1096A (orange bars) mutants were also included and their expression
levels are shown in lanes 4–6 of the corresponding western blot.
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Figure 4. SMG6 interacts with UPF1 HD in a phospho-independent manner. (A) Diagram of the UPF1 aspect of various GAL4-DNA-BD-UPF1 con-
structs tested. (B) Yeast two-hybrid data. In rows 1–6, plasmids expressing GAL4-DNA-binding domain UPF1 fusion protein (BD-UPF1) and derivatives
thereof were co-transformed with a plasmid expressing GAL4-activation domain SMG6 fusion protein (AD-SMG6) into Mav99 cells. The designated
co-transformations in rows 7–14 were performed as negative controls, where BD only represents transformation of a plasmid expressing GAL4-DNA-
BD-empty and AD only represents transformation of a plasmid expressing GAL4-AD-empty. In row 15, plasmids expressing GAL4-DNA-BD-eRF3a
co-transformed with a plasmid expressing GAL4-AD-eRF1 served as a positive control, along with the necessary controls in rows 16–17. Four colonies
(denoted as A–D) from each co-transformationwere selected for the -galactosidase plate assay. An interaction between the BD and theAD fusion proteins
activates -galactosidase expression, which produces a blue color by hydrolyzing X-gal. (C) Top: PyMOL view of the structure of human UPF1 HD based
on pdb file 2xzp (30) showing the two RecA domains (in green), the additional protruding sub-domains 1B and 1C (both in black) along with the stalk
helices (in orange). Bottom: schematic of the UPF1 part of the additional GAL4-DNA-BD-UPF1 constructs tested. Note the same deletions were created
and tested in full-length UPF1. (D) As in (B), except the co-transformations were performed using plasmids expressing the stipulated GAL4-DNA-BD-
UPF1 proteins (BD-UPF1) with the plasmid expressing GAL4-DNA-AD-SMG6 (AD-SMG6) shown in rows 1–8. Rows 9–16 represent the corresponding
negative controls expressing empty GAL-AD (AD only).
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Figure 5. UPF1 Stalk and SQ regions are involved in binding to SMG6 in vitro. (A) Schematic of the tested UPF1 constructs. UPF1WT, Stalk and 1C
were defined in Figure 4C. UPF1 Stalk SQ1 and UPF1 Stalk SQ2 lack the last 99 or all 204 AA of the UPF1 SQ domain (in blue), respectively.
(B) Twenty percent of Flag-HA-SBP-MBP (as control) or Flag-HA-SBP-SMG6 bound to anti-HA magnetic beads were eluted in SDS sample buffer,
subjected to SDS-PAGE and stained and visualized with ORIOLE fluorescent gel stain. The positions of the full-length proteins and the lgG light chain
are marked by black dots and LC, respectively. (C, E) Hundred nanograms of the indicated proteins, expressed in 293T cells and purified using SBP-tag
affinity chromatography, were separated on an SDS-PAGE and as in (B). Black dots (•) and asterisk (*) indicate the positions of purified proteins and
a degradation product of UPF1 Stalk, respectively. (D, F) Pull-down assays testing the interaction of SMG6 with UPF1 mutants. Flag-HA-SBP-MBP
(as control) or Flag-HA-SBP-SMG6 immobilized on anti-HA magnetic beads were incubated with the indicated SBP-tagged purified proteins (1000 nM
each). Seventeen percent of each sample was set aside as input and subjected to SDS-PAGE (lanes 1–4 in (D) and lanes 1–5 in (F)) and the remaining
material was precipitated and subjected to SDS-PAGE (lanes 5–12 in (D) and lanes 6–15 in (F)). UPF1, eGFP and HA-tagged MBP and SMG6 were
detected by immunoblotting using the indicated antibodies.
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Figure 6. Purified UPF1 Stalk still interacts with RNA. (A–E) RNA binding studies using MicroScale Thermophoresis (MST). By fitting the change in
thermophoretic depletion upon titration of (A) UPF1WT, (B) UPF1 Stalk, (C) UPF1 1C, (D) SMG6 and (E) eGFP to a constant amount (20 nM) of
Cy5-labeled U30 RNA to the quadratic solution of the mass action law, the binding constants in nM (KD) were determined. The normalized fluorescence
(Fnorm) is plotted on a linear y-axis in per thousand () against the total concentration of the titrated protein (nM) on a log10 x-axis. At least two independent
measurements were made for each assay and error bars on the individual data points represent the SD between these repetitions.
of 500 nM down to 0.015 nM (with the exception of SMG6
that was diluted from 350 nM to 0.01 nM) in the presence
of constant labeled RNA (20 nM). The RNA–protein mix-
tures were analyzed in hydrophilic capillaries (NanoTemper
Technologies ref: K004) using the Monolith NT.115TMST
instrument (NanoTemper Technologies) at room tempera-
ture (RT), where the light-emitting diode (LED) was set at
40% (except in Figure 6E where the LED was set to 70%),
the IR-laser power was set at 20% and laser on and off times
were fixed at 30 s and 5 s, respectively. The Nanotemper
Technologies Analysis software, version 1.5.41, was used to
obtain normalized fluorescence versus concentration curves
and to determine the corresponding KD using the law of
mass action.
RESULTS
Tethering of the SMG6 PIN domain alone is not sufficient to
reduce reporter RNA levels
To build upon what is known about SMG6 and further de-
lineate the molecular mechanisms surrounding SMG6 ac-
tivity, we established an SMG6 TFA, a comprehensive de-
scription of which can be found elsewhere (29). Full-length
SMG6, mutants thereof and a fragment of LacZ serving as
a control were fused to the MS2 coat protein, which in turn
can be artificially tethered to a -globin reporter mRNA
containing six MS2 binding sites in its 3′-untranslated re-
gion (3′UTR) (-globin-6-MBS; Figure 1A). SMG6-MS2
fusion proteins were co-expressed with the -globin-6-MBS
reporter and a GFP expressing plasmid in HeLa cells, and
the steady-state levels of the reporter mRNA were quan-
tified and normalized to the levels of GFP mRNA. Ex-
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Figure 7. Functional assays confirm that the phospho-independent interaction between UPF1 and SMG6 is crucial for NMD. (A) SMG6-TFA completed
as in Figure 3B, except the plasmid expressing RNAiR UPF1 Stalk (blue bars) was also included. The knockdown was extended by 1 day in these
experiments and the bars represent the mean of three independent experiments. Error bars are SD and P-values are show in Supplementary Figure S1D.
Western blot showing UPF1 levels. Lanes 1–3 represent a serial dilution (100, 33 and 11%) of cell lysate from untransfected HeLa cells. Lane 4 represents
control shRNA (Ctr) and lane 5 represents the samples expressing two shRNAs targeting UPF1. Lanes 6 and 7 represent the samples expressing the
shRNAs targeting UPF1 and the exogenous expression of RNAiR UPF1 WT and UPF1 Stalk, respectively. The detected protein is indicated on the
right of the blot. (B) NMD rescue assays. HeLa cells were transfected with plasmids expressing mini- mRNA with a PTC at position 310 ( Ter310),
pmCMV-rGPx1-TGC, serving as a co-transfection control and with plasmids expressing either a control shRNA or shRNAs targeting UPF1 and where
indicated plasmids expressing RNAiR UPF1 WT or RNAiR UPF1 Stalk were also co-transfected. RT-qPCR analysis was used to evaluate the relative
 mRNA levels, normalized to GPx1 mRNA levels, and the levels of normalized WT mRNA in control knockdown cells were set to 100% (not shown
for clarity). The bars represent the mean of three independent experiments. Error bars are SD and P-values are show in Supplementary Figure S1D. Right
panel: western blots from  Ter310 expressing cells are as in (A). (C) Performed and analyzed as in (B), except plasmids expressing -globin mRNA with
a PTC at position 39 (-globin Ter39) were co-transfected.
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pression of SMG6-MS2-HA reduced the steady-state lev-
els of the reporter mRNA to below 10% of the levels de-
tected in cells expressing the LacZ-MS2-HA or the HA-
MS2-LacZ controls, which encode a fragment of the -
galactosidase fused to a C-terminally located MS2-HA or
an N-terminally located HA-MS2 moiety, respectively. To
control for potential pleiotropic effects caused by over-
expression of proteins, SMG6 without theMS2-moiety was
also tested (Figure 1B).Western blotting confirmed that the
MS2 fusion proteins and the SMG6 lacking the MS2 moi-
ety were all expressed (Figure 1B, lower panels).
To address what aspect of SMG6 was important
for inducing reporter level reduction when tethered to
the mRNA, we expressed various SMG6 mutants fused
to MS2-HA (Figure 1C). In the SMG6-PIN mutant
(SMG6mPIN), the endonuclease activity was abolished by
mutating the three crucial aspartic acids in the catalytic
center to asparagines (24). In the SMG6-14-3-3 mutant
(SMG6m14-3-3), four highly conserved amino acids in the
14-3-3-like domain were changed (19) with the expecta-
tion that this should prevent SMG6 from binding to UPF1
phosphorylated at T28, as previously shown with such an
SMG6 mutant (18). Finally, in the SMG6 EBM mutant
(SMG6mEBM), point mutations were introduced in the
EBMs 1 and 2 in the very N-terminus of SMG6 (20). Trans-
fection conditions were adapted to achieve a similar expres-
sion of all of the SMG6-MS2-HA mutants as displayed in
the western blot in the lower part of Figure 1D. When teth-
ered to the -globin reporter mRNA, we observed that the
SMG6mPIN-MS2-HA did not reduce the reporter RNA
levels at all (Figure 1D). By contrast, the SMG6m14-3-3-
MS2-HA behaved like its wild-type counterpart and was
able to reduce the reporter RNA levels to ∼12% of the lev-
els detected in cells expressing the LacZ-MS2-HA control.
Finally, the ability of the tethered SMG6mEBM-MS2-HA
in reducing the reporter RNA levels was significantly com-
promised compared to tethering wild-type SMG6 (P-value
3.9× 10−5; see Supplementary Figure S1A) yet significantly
different from the LacZ-MS2-HA control (P-value 1.5 ×
10−11). The same results were reached when the -globin
RNA levels were analyzed by northern blotting and also
when the same SMG6 fusion proteins were tethered to a
Renilla luciferase reportermRNAcontaining sixMS2 bind-
ing sites in its 3′UTR (Supplementary Figure S2). Next,
we wondered if tethering of the PIN domain alone was
enough to elicit decreased -globin reporter mRNA levels.
As shown in Figure 1E, tethering the SMG6 PIN domain
alone was not sufficient to bring about the reduction in re-
porter mRNA levels. Expression of the PIN-MS2-HA and
mPIN-MS2-HA are documented in lanes 2 and 3 of the ac-
companying western blot.
In summary, mutations affecting the N-terminal EBM
motifs compromise the ability of SMG6 to reduce reporter
mRNA levels despite the fact that their proposed role of
recruiting SMG6 to the RNA (20) is bypassed in these as-
says, begging the question as to what function these mo-
tifs contribute to the endonuclease activity of SMG6. The
SMG6 14-3-3 mutant that should no longer be able to inter-
act with P-UPF1 induced reporter mRNA reduction as well
as its wild-type SMG6, consistent with the view that nor-
mally SMG6 is recruited to NMD-targeted messenger ri-
bonucleoprotein particles (mRNPs) by this interaction and
our tethering assay bypasses this requirement. Importantly,
the endonucleolytic activity of SMG6 is required but not
sufficient by itself for inducing reporter mRNA level reduc-
tion, demonstrating that additional parts of the SMG6 pro-
tein are necessary for endowing the PIN domain with en-
donuclease activity, presumably by interacting with addi-
tional proteins.
The SMG6-mediated reportermRNA level reduction requires
SMG1 and UPF1
To test whether additional NMD factors are required to
stimulate the endonuclease activity of SMG6, we performed
TFAs with the SMG6-MS2-HA constructs described in
Figure 1 in HeLa cells depleted of various NMD factors.
UPF1, UPF2, SMG1, SMG5 or SMG7 was knocked down
by expressing corresponding shRNAs in parallel with a
control pSUPuro plasmid expressing a scrambled sequence
with no predicted specific targets in human cells. A frac-
tion of the cell lysates were used to extract RNA and de-
termine the relative -globin reporter mRNA levels (see be-
low), and western blots were performed with the remainder
of each lysate to assess the knockdown efficiencies of the
stipulated NMD factors (Figure 2A). The effectiveness of
the stipulated RNAi-mediated knockdowns was also docu-
mented at themRNA level (Supplementary Figure S3A–E).
The -globin reporter mRNA level for each experimental
condition is depicted relative to the level in cells express-
ing LacZ-MS2-HA and normalized to GFP mRNA en-
coded on a co-transfected expression plasmid to account
for differences in transfection efficiencies among the sam-
ples (Figure 2B–D and Supplementary Figure S1B). We
found that SMG6-MS2-HA-induced reporter mRNA level
reduction significantly requires UPF1 and SMG1 but is
only marginally compromised by the knockdown of UPF2,
SMG5 or SMG7 (Figure 2B). Essentially the same result
was obtained when SMG6m14-3-3-MS2-HA was tethered
(Figure 2C). The already compromised destabilizing activ-
ity of the SMG6mEBM was also lost under UPF1 and
SMG1 knockdown conditions (Figure 2D). Intriguingly,
the modest reduction of reporter RNA induced by teth-
ering of SMG6mEBM was further lost when UPF2 was
knocked down, in contrast to tethered SMG6 wild-type,
whichwas barely affected byUPF2.Knockdown ofUPF3B
gave a similar result; it barely affected the strong drop in re-
porter mRNA levels induced by tethering wild-type SMG6,
but it significantly abrogated the modest decrease of re-
porter levels induced by tethering of SMG6mEBM (Sup-
plementary Figures S3F and G and S1E). This suggests
that UPF2 and UPF3B are also involved in activation of
the SMG6 endonuclease under physiological conditions but
possibly their contribution is weaker than those of UPF1
and SMG1, and hence it can only be detected under con-
ditions that reduce the otherwise dominant contributions,
such as in the case of the EBM mutant. In summary, the
data identify UPF1 and SMG1 as necessary co-factors for
the endonuclease activity of SMG6 and also indicate a mi-
nor involvement ofUPF2 andUPF3B. In contrast, the roles
of SMG5 and SMG7 seem marginal at best in our SMG6
TFA.
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Rescue experiments confirm that SMG6 activity requires
UPF1 and SMG1
To ascertain that the loss of the SMG6 induced reporter
mRNA level reduction was specifically caused by the de-
pletion of SMG1 and UPF1 and not by an off-target effect
of the knockdown, we tried to rescue the observed SMG6-
mediated effect on the mRNA reporter by expression of
exogenous RNAiR versions of these proteins. Figure 3A
depicts the SMG1 rescue experiment where the specified
SMG6-MS2-HA constructs, or the controls LacZ-MS2-
HA and HA-MS2-LacZ, were tethered in HeLa cells ex-
pressing a control shRNA (black bars), cells depleted of
SMG1 (gray bars) or cells depleted of SMG1 and expressing
exogenous RNAiR SMG1 (green bars). Our data show that
expression of RNAiR SMG1 significantly and specifically
rescues the steady-state reportermRNA levels back to those
observed under no knockdown conditions (see Supplemen-
tary Figure S1C for P-values). Western blotting confirmed
that the RNAi mediated SMG1 knockdown was effective
and that the expression of the exogenous RNAiR SMG1 re-
plenished the pool of intracellular SMG1 to a similar level
as without or with a control knockdown. The UPF1 res-
cue experiment was analogously performed and gave a sim-
ilar result (Figure 3B and Supplementary Figure S1C). It
showed that exogenously expressed RNAiRUPF1 was able
to significantly rescue the mRNA reporter levels under en-
dogenous UPF1 knockdown conditions back to those seen
in HeLa cells with a control knockdown. As for SMG1,
western blotting confirmed that the UPF1 knockdown was
effective and that the expression of the RNAiR UPF1 in
cells depleted of UPF1 yielded UPF1 protein levels sim-
ilar to those observed in cells without or with a control
knockdown. These results confirm that tethered SMG6-
mediated reporter mRNA level reduction definitively re-
quires the presence of both UPF1 and SMG1.
UPF1 phosphorylation mutants still support SMG6-
facilitated RNA reporter level reduction, regardless of the
need for SMG1 and UPF1
To decipher the domains or functions of UPF1 and SMG1
required for the activity of SMG6, RNAiR UPF1 con-
structs harboring various previously described mutations
were expressed in SMG6 tethering rescue experiments. We
tested three different UPF1 phospho-site (P-site) mutants:
T28A, S1096A and a double mutant comprising both of
these point mutations (18). As before, the UPF1 knock-
down effectiveness and the expression levels of the RNAiR
UPF1 constructs were monitored by western blotting (Fig-
ure 3C, right panel). The efficient UPF1 knockdown was
determined (lane 2) and the levels of all RNAiR UPF1 mu-
tants (lanes 4–6) were comparable to the endogenous UPF1
levels in control knockdown cells (lane 1). As previously
observed (Figure 3B), wild-type RNAiR UPF1 rescued the
increased mRNA reporter levels resulting from the loss of
UPF1 back to the levels observed when the assay was per-
formed without knockdown (Figure 3C, red bars). Interest-
ingly, RNAiR UPF1-T28A (pink bars) and UPF1-S1096A
(brown bars) rescued the reduced reporter levels induced by
SMG6 as efficiently as wild-type UPF1 (all P-values >0.1
when compared to the effect induced by SMG6 under con-
trol knockdown conditions; Supplementary S1C) and even
the double mutant T28A/S1096A (orange bars) was almost
as effective as the wild-type counterpart in these SMG6
tethering rescue experiments (the P-values when compared
to the other P-site mutant rescues are >0.1 but the P-value
is 0.01 compared to the control knockdown condition).
This result was unexpected in light of the previously
reported dependence of the UPF1–SMG6 interaction on
phosphorylated T28 in UPF1 (18). Therefore, we wanted to
confirm that the mutants designed to disrupt the reported
interaction between P-UPF1 and SMG6 were success-
fully abolishing such an interaction in our assays. Hence,
we co-expressed HA-UPF1 with our various SMG6 mu-
tants fused to MS2-HA and performed immunoprecipita-
tions (IPs) with an anti-MS2 antibody (MS2-IP) to test
the SMG6-MS2-HA proteins for their ability to co-IP P-
UPF1 (Supplementary Figure S4A). Since only a very
small fraction of UPF1 is phosphorylated at steady state
(39), we co-expressed HA-UPF1 and added okadaic acid
(a potent inhibitor of serine/threonine phosphatases 1,
2A and 2B) prior to cell lysis to increase the abundance
of intracellular P-UPF1 (40). Intriguingly, all of the de-
scribed SMG6-MS2-HA proteins co-immunoprecipitated
P-UPF1 (lanes 6, 9, 12, 15 and 18) as determined by us-
ing a phospho-(Ser/Thr) ATM/ATR substrate antibody
that specifically recognizes P-UPF1 at the correct molec-
ular weight, albeit, we observed that the SMG6mEBM-
MS2-HA and the SMG6m14-3-3-MS2-HA versions co-
precipitated much less P-UPF1 than the SMG6-MS2-HA
wild-type and SMG6mPIN-MS2-HA constructs (compare
lanes 12 and 15 with 6 and 9, respectively). Furthermore, we
detected a small and similar fraction ofUPF1 in the precipi-
tates of all SMG6-MS2-HA constructs using an anti-UPF1
antibody, even when the lysate was treated with RNase
A (lane 18). In contrast, the LacZ-MS2-HA control did
not co-IP any P-UPF1 (lane 3). In a vice-versa approach,
we expressed our MS2-UPF1 P-site mutants together with
HA-SMG6, performed MS2-IPs and examined the extent
of SMG6 co-precipitation (Supplementary Figure S4B).
Noteworthy, the MS2-UPF1-T28A still co-precipitated a
small fraction of SMG6 (lane 9). In fact, all of the UPF1
P-site mutants still weakly co-precipitated SMG6 (lanes 12
and 15), to a similar or slightly lesser extent than the wild-
type UPF1 protein and regardless of RNase A treatment
(lanes 6 and 18, respectively). HA-MS2-LacZ did not co-IP
any SMG6 which confirmed the specificity of the IPs (lane
3).
Given that the UPF1 P-site mutants still co-
immunoprecipitated with SMG6, we wondered whether the
kinase activity of SMG1 was required for SMG6-mediated
RNA decay in the TFA or whether perhaps another
function of SMG1 supported SMG6 activity. Therefore,
RNAiR SMG1 D2331A where the kinase activity was
abolished by mutating a crucial aspartic acid in the PIKK
catalytic domain to an alanine (41,42) was expressed in
the SMG6 TFA. As previously observed (Figure 3A),
wild-type RNAiR SMG1 rescued the increased mRNA
reporter levels resulting from the loss of SMG1 back to
the levels observed when the assay was performed without
knockdown (Supplementary Figure S5A, green bars and
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Supplementary Figure S1F for P-values). In contrast, the
RNAiR SMG1 D2331 (purple bars) did not rescue the
SMG6-induced reduced reporter RNA levels. The effi-
cient SMG1 knockdown was determined (Supplementary
Figure S5B, lane 5) and the levels of RNAiR SMG1 WT
and the D2331A mutant (lanes 6 and 7) were comparable
to the endogenous SMG1 levels in untreated cells and in
the control knockdown cells (lanes 1 and 4, respectively).
This result indicates that SMG1 kinase activity is required
for SMG6 activity in the TFA. Since tethered SMG6
needs UPF1 and kinase-competent SMG1 for decreasing
the reporter mRNA levels, suggesting a requirement for
P-UPF1, while on the other hand the phospho-epitope
binding SMG6 14-3-3 mutant still induced strong reporter
mRNA level loss and the UPF1 T28A and S1096Amutants
rescued SMG6-mediated effects on the reporter mRNA
in UPF1 knockdown cells as efficiently wild-type UPF1,
we conclude that these SMG1-mediated phosphorylation
events needed for SMG6 activity occur either in other
proteins or in UPF1 at P-sites other than T28 and S1096.
Moreover, we discovered that more of the SMG6 protein
than just the PIN or 14-3-3 domain was needed for its ac-
tivity and we always observed a minor but constant interac-
tion between UPF1 and SMG6, regardless of the mutations
made in either protein. Based on all of this, we postulated
that at least a part of the SMG6–UPF1 interaction may oc-
cur in a phosphorylation-independentmanner as previously
hinted to but never explored (18,20). We anticipated that
such a phospho-independent interaction might contribute
a regulatory aspect to each enzyme and would be important
for the actual mRNA degradation induced by SMG6.
Discovery of a phosphorylation-independent interaction be-
tween SMG6 and the helicase domain of UPF1
To identify such a phospho-independent interaction be-
tween UPF1 and SMG6, we utilized the yeast two-hybrid
system (43). First, we tested several truncations of UPF1
(Figure 4A) fused to the GAL4-DNA-binding domain
(BD) for an interaction with full-length SMG6 fused to
the GAL4-activation domain (AD) using a LacZ reporter
gene, which allows detection of colonies expressing -
galactosidase by addition of the chromogenic substrate X-
gal to the plates. Of each co-transformation, four different
colonies (A–D) were analyzed. GAL4-DNA-BD-eRF3a
and GAL4-AD-eRF1 served as positive control since the
interaction between eRF1 and eRF3 is well documented
(44,45) (Figure 4B, row 15). Additional controls ruled out
self-activation of any of the GAL4-DNA-BD fusion pro-
teins in the absence of the GAL4-AD-SMG6 (Figure 4B,
rows 8–14) while the control shown in row 7 confirmed that
GAL4-AD-SMG6 is also not able to self-activate the re-
porter gene. Co-expression of BD-UPF1 and AD-SMG6
resulted in blue colonies, indicating an interaction between
the UPF1 and SMG6 full-length proteins (row 1). While we
did not observe any interaction between SMG6 and the CH
or SQ domains of UPF1 (rows 2 and 4), we scored an in-
teraction between the UPF1 HD domain and SMG6 (row
3), which was abolished by the presence of the CH domain
(row 5). On the other hand, we noted that the interaction
between the UPF1 HD and SMG6 appeared consistently
stronger when the HD still had its SQ domain present (row
6). These results indicate that the presence of the CH do-
main inhibits and the presence of the SQ domain enhances
the interaction of SMG6 with the UPF1 HD. The expres-
sion levels of the utilizedUPF1 constructs and of the SMG6
full-length construct in yeast cells were confirmed by west-
ern blotting using an anti-c-Myc antibody recognizing the
in-frame c-Myc tag located between the DNA-BD and the
start of the UPF1 ORF and an anti-HA antibody identify-
ing the in-frame HA-epitope tag located between the AD
and the start of the SMG6 ORF (Supplementary Figure
S6A and B, respectively).
As illustrated in the crystal structure of the UPF1 HD
(30) in Figure 4C, it consists of two domains shown in green,
each of which comprises RecA-like / domains that are
responsible for nucleotide and RNA binding and have been
referred to as RecA1 (or 1A) and RecA2 (or 2A), respec-
tively (30,46). The adenosine triphosphate (ATP) binding
site is located in a deep cleft separating these two RecA-
like domains. On the first domain, two further sub-domains
termed 1B and 1C exist (shown in black). 1B comprises
amino acids (AA) 325-414 and takes the form of a -
barrel consisting of six anti-parallel strands located above
the boundary between the two RecA-like domains (6,46–
47). 1B is connected to RecA1 by two -helices that are
not preserved in any other known helicase structures. These
two -helices were termed the stalk (colored in orange) be-
cause they protrude from RecA1 (30). 1C comprises AA
556-609 and is made up of three helices that pack against
the outer surface of Rec1A and makes a few contacts to
sub-domain 1B. Since the 1B and 1C insertions are unique
for UPF1, form structural entities above the RecA-like do-
mains and seem to be important for NMD, at least in yeast
(30,46), we wondered if SMG6 interacted with these struc-
tures, which would confer specificity in the UPF1–SMG6
interaction. To test this, we generated full-length UPF1,
UPF1 HD or UPF1 HD-SQ fused to the GAL4-DNA-
BD that lacks the stalk plus the intervening 1B insertion
(Stalk, AA 271-433), the 1C sub-domain (1C, AA 561-
608) or both (Stalk1C) as illustrated in Figure 4C below
the crystal structure. When tested in the yeast two-hybrid
assay, we found that even when the 1C region is removed
from the UPF1 HD, it still interacted with SMG6 (Figure
4E, rows 4, 5 and 8). Notably, the enhancing effect of the
presence of the SQ domain was again clearly seen in these
tests (compare rows 4 and 5). However, when the stalk re-
gion was removed, the interaction was lost (Figure 4D, rows
1–3 and 6–7). This dependence on the stalk region strongly
suggested that the interaction point of UPF1 with SMG6
lies somewherewithinAA271-433. Again, the negative con-
trols ruled out self-activation of the various protein fusions
alone (rows 9–16).
Given that this result is based upon a loss of interaction,
it was essential to confirm by western blotting that the con-
structs depicted in Figure 4C and assayed in Figure 4Dwere
all made into proteins in the yeast cells (Supplementary Fig-
ure S6C). We could not detect expression of the BD-UPF1
HD Stalk construct (not shown), but we could detect ex-
pression of the same mutant incorporated into BD-UPF1-
HD-SQ (left panel, lane 3) and in full-length UPF1 (right
panel, lane 8).
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Concurrently with mapping the region in UPF1 required
for this novel interaction betweenUPF1 and SMG6,we also
tried to identify the interaction point to UPF1 in SMG6 us-
ing the yeast two-hybrid approach. We constructed several
plasmids encoding the different SMG6portions fused to the
GAL4-AD but we were not able to conclusively map the in-
teraction point in SMG6 becausemany of the SMG6 fusion
proteins involving the unstructured N-terminus were not
well expressed in the yeast cells (data not shown). However,
SMG6 PIN domain (AA 1239-1419), 14-3-3 domain (AA
576–814) and SMG6 AA 814-1419 fused to the GAL4-AD
all expressed well in the yeast cells but we did not observe
an interaction of any of these SMG6 fusion proteins with
UPF1 (Supplementary Figure S6D and E). The interaction
between UPF1 and SMG6 14-3-3 domain is probably re-
liant upon phosphorylation and the yeast cells lack SMG1
to phosphorylate UPF1 for this to occur (12). Therefore,
it is clear that the interaction between SMG6 and UPF1
probably involves the N-terminal part of SMG6 and is not
mediated by the PIN domain of SMG6.
UPF1 Stalk and SQ regions are involved in binding to SMG6
in vitro
We next analyzed in vitro the binding between SMG6 and
UPF1 to confirm the interaction identified using the yeast
two-hybrid assay by testing if purified SMG6 can pull-
down purified UPF1 and variants thereof depicted in Fig-
ure 5A. Specifically, Flag-HA-SBP-SMG6 and Flag-HA-
SBP-MBP, serving as a control were expressed inHEK293T
cells and captured on anti-HA magnetic beads (Figure 5B)
and streptavidin-binding protein (SBP) tagged UPF1 WT,
UPF1 Stalk, UPF1 1C and eGFP were expressed in
HEK293T cells. Such cells were treated with 7-mM caffeine
for 4 h to abolish UPF1 phosphorylation and affinity pu-
rified using streptavidin sepharose (Figure 5C). Aliquots
of immobilized Flag-HA-SBP-SMG6 and Flag-HA-SBP-
MBP were mixed with equimolar amounts of the purified
UPF1 protein variants or with eGFP as a control and the
retained proteins were detected by western blot using an
anti-UPF1 or anti-GFP antibody, respectively (Figure 5D).
All three UPF1 protein variants co-precipitated specifically
with Flag-HA-SBP-SMG6 but the amount of SMG6 as-
sociated with UPF1 Stalk was reduced compared with
UPF1 WT and UPF1 1C (Figure 5D, compare lane 11
with lanes 10 and 12, respectively). This result corroborates
our yeast two-hybrid data by confirming that the stalk re-
gion is an important part of UPF1 for its interaction with
SMG6. Since we consistently observed in our yeast two-
hybrid analyses that the SQ domain of UPF1 enhanced
the binding between UPF1 and SMG6 (Figure 4) and re-
moval of the stalk region did not completely abolish the
interaction between SMG6 and UPF1, we also tested if
the SQ domain of UPF1 contributes to the interaction.
Thus, two additional SBP-tagged C-terminally truncated
UPF1 Stalk constructs lacking the last 99 amino acids
(UPF1 StalkSQ1; see Figure 5A) or the entire SQ do-
main (StalkSQ2) were also expressed in HEK293T cells
as before (Figure 5E). Again, the UPF1 WT protein co-
precipitated specifically with Flag-HA-SBP-SMG6 (Fig-
ure 6F, lane 11) and the amounts of SMG6-associated
UPF1Stalk andStalkSQ1 were reduced to similar ex-
tents compared with UPF1 WT (Figure 5F, compare lane
11 with lanes 12 and 13, respectively). Strikingly, almost
no UPF1 StalkSQ2 was pulled down by SMG6 (lane
14). Therefore, the UPF1 Stalk region of the HD and the
proximal 105 amino acids of the UPF1 SQ domain are in-
volved in binding to SMG6. This result is in line with the
fact that Chakrabarti et al. also simultaneously detected a
contribution of the SQdomain to this newly identified inter-
action between UPF1 and SMG6 (48) . Since yeast cells do
not appear to have an SMG1 ortholog (12) and because the
UPF1 used in our in vitro assays was hypo-phosphorylated,
this identified interaction between UPF1 and SMG6 likely
occurs independently of phosphorylation. Further to this,
there are no annotated P-sites existing within the UPF1 re-
gion spanning AA 271-433 and the two annotated P-sites
in the proximal SQ domain at Y946 and Y958 are not well
conserved and have not been site-specifically analyzed so far
(49,50).
UPF1 Stalk can still bind RNA while UPF1 1C has a
greatly reduced affinity for RNA in vitro
The activity of the UPF1 HD is regulated by its neighbor-
ing N-terminal histidine-rich (CH) domain and C-terminal
SQ domain. The CH domain of UPF1 makes intramolec-
ular connections to HD which seems to hide its enzy-
matic activity and this repression is only alleviated when the
UPF2/UPF3 complex binds to the CH domain, which in-
duces a large conformational change causing UPF1 to re-
lax its grip on the RNA and leading to the activation of
UPF1ATPase/helicase activity (30,51,52). Similarly, the C-
terminal region of humanUPF1 also appears to interact di-
rectly with the HD to suppress UPF1 enzymatic activities.
Again, this repression is only diminished when a currently
unknown factor binds to the area of the SQ proximal to the
HD, causing a rearrangement allowing for enzymatic acti-
vation (53). Ultimately these regulatory effects are a conse-
quence of tempering with the extent of RNA binding and
the sub-domains 1B and 1C of theHDhave been implicated
to be important in controlling RNA binding (30,46).
Given the postulated roles of 1B and 1C in UPF1’s RNA
binding behavior, it was vital to examine how deletions of
the stalk region (encompassing sub-domain 1B) and the
sub-domain 1C in theHD affect the ability of UPF1 to bind
single-stranded RNA. We wanted to know whether the re-
duced interaction between UPF1 Stalk and SMG6 was
due to the loss of an interaction point or due to a damag-
ing effect on the ability of UPF1 to bind RNA. Moreover,
we also wanted to test if SMG6 could bind to RNA itself.
Therefore, interactions of our recombinant proteins with
RNA were examined in solution using MST (38). We used
fluorescently labeled U30 RNA at a fixed concentration (20
nM) and titrated the unlabeled designated protein partner
in a range starting at concentrations above the expected dis-
sociation constant (KD) and ending with sub-stoichiometric
concentrations with respect to the labeled RNA. Under our
experimental conditions, UPF1 exhibited a high affinity for
RNA with a calculated KD of 1.48 nM (Figure 6A). Dele-
tion of the stalk/1B structure led to a moderate weakening
of the interaction betweenUPF1 andRNA (KD of 6.51 nM)
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(Figure 6B). In contrast, deletion of the 1C region dramati-
cally reduced UPF1’s binding affinity for RNA by 32.2-fold
compared to UPF1WT (Figure 6, compare A and C). Con-
trary to another study (54), we found no evidence for bind-
ing of SMG6 to RNA in our assay (Figure 6D). Finally, we
did not observe eGFP binding to RNA, which served as a
control in these assays (Figure 6E). Thus, our result indi-
cates that SMG6 has to be recruited to its target mRNAs
by a protein–protein interaction, for example by UPF1.
Furthermore, we validated the functionality of the re-
combinant full-length SMG6 protein in vitro by perform-
ing endocleavage assays.Wild-type SMG6protein degraded
a radioactively labeled U30 RNA while its endonucleolyti-
cally inactive counterpart could not degrade the RNA. We
also demonstrated that this ribonuclease activity requires
Mn2+ (Supplementary Figure S7) as was shown by Glavan
et al. using bacterially produced SMG6 PIN domain (21).
SMG6 activity in these in vitro assays was poor and we am-
bitiously tried to increase the activity of SMG6 by adding
UPF1. However, we did not conclusively find UPF1 to pro-
mote SMG6 activity in these assays, most likely because we
were still lacking other regulatory factors that are essential
for optimal SMG6 activity (data not shown).
In conclusion, we have shown that only the deletion of
1C abrogated the ability of UPF1 to effectively bind RNA,
which is in line with earlier results using filter binding as-
says (46), while the UPF1 Stalk protein is able to bind
RNA. This strongly indicates that our observed loss of in-
teraction betweenUPF1Stalk and SMG6 observed in the
yeast two-hybrid assays and in the in vitro pull-down assays
is not because UPF1 can no longer bind RNA but rather
due to the fact that the stalk region of the UPF1 HD (AA
271-433) encompasses a phosphorylation-independent in-
teraction surface for SMG6.
It had not escaped our attention that the stalk region
includes the area of difference between human UPF1 iso-
form 1 (UniProtKB: Q92900-1) and isoform 2 (Q92900-2).
Compared to hUPF1 isoform 1, isoform 2 lacks AA 353-
363 (Supplementary Figure S8A) due to the usage of an al-
ternative 5′ splice site in exon 7. Both isoforms have been
used in publications but possible functional differences be-
tween them have never been examined. So far, we had only
worked with UPF1 isoform 2 and thus we wanted to ex-
amine if the extra 11 amino acids in isoform 1 altered the
affinity of UPF1 for SMG6. HeLa cells produce mRNAs
for both isoforms, with isoform 2 being the more abun-
dant isoform (Supplementary Figure S8B). Similar to re-
sults gained using UPF1 isoform 2 in Figure 4B, we found
that small amounts of SMG6 also co-immunoprecipiated
with MS2-UPF1 iso1 (Supplementary Figure S8C) and
RNAiR UPF1 iso1 was able to rescue the ability of SMG6
to induce reporter mRNA level reduction as efficiently as
RNAiR UPF1 iso2 (Supplementary Figure S8D). In addi-
tion, both isoforms were able to restore NMD of different
PTC-containing Ig- and TCR reporter mRNAs in cells
with reduced endogenous UPF1 isoform 1 and 2 protein
levels (data not shown). These data suggest that both iso-
forms of UPF1 can support the mapped interaction with
SMG6 in human cells.
The interaction between the UPF1 Stalk region and SMG6
is crucial for SMG6 activity in the TFA and for NMD
To determine the functional significance of the interaction
between UPF1 HD and SMG6, we first examined how im-
portant the stalk region of the HD of UPF1 was to the
induction of SMG6-mediated mRNA reporter level reduc-
tion. The SMG6 TFA was performed as before, along with
an RNAi-mediated depletion of endogenous UPF1 and ex-
pression of RNAiR UPF1Stalk. As shown in Figure 7A
and Supplementary Figure S1D, the RNAiR UPF1 Stalk
(blue bars) was not able to rescue the steady-state mRNA
reporter levels under UPF1 knockdown conditions back to
those seen in HeLa cells with a control knockdown. No-
tably, the UPF1 knockdown in this experiment was pro-
longed by 1 day, which accounts for the stronger effects
observed in the UPF1 knockdown conditions compared
those documented in Figure 3C. As shown in the western
blot, the RNAiRUPF1 versions were detected in cells lack-
ing endogenous UPF1 and were each expressed to a simi-
lar level as their wild-type counterpart (Figure 7A, lanes 6
and 7). This result confirmed a functional necessity for the
UPF1 stalk region in SMG6-mediated degradation of re-
porter mRNA levels.
In addition, we also performed classical NMD assays us-
ing two well-characterized NMD reporter genes, one based
on an immunoglobulin  mini-gene (55) and the other on
the-globin gene (56).We enforcedUPF1 knockdowns and
rescued the loss of NMD using RNAiR UPF1 WT as well
as RNAiR UPF1Stalk. As anticipated, the levels of the 
Ter 310 and -globin Ter 39 reporter mRNAs were reduced
to less than 1% of their corresponding wild-type counter-
parts due to NMD (Figure 7B and C, respectively, and Sup-
plementary Figure S1D). Depletion of UPF1 and hence
abolishment of NMD caused the  Ter 310 and -globin
Ter 39 reporter mRNA levels to increase by over 10-fold.
When RNAiR wild-type UPF1 was expressed, the  Ter
310 and-globin Ter 39 reportermRNA levels were rescued
almost back to that observed in the control-treated cells.
In contrast, no rescue at all was observed when RNAiR
UPF1Stalk was expressed. Western blotting confirmed
that the UPF1 knockdown was efficient (Figure 7B, lane
5) and that the expression of the RNAiR UPF1 versions
in cells depleted of endogenous UPF1 yielded UPF1 pro-
tein levels similar to those observed in cells without or with
a control knockdown (compare lanes 6 and 7 with 1 or 4,
respectively). Similarly, the accompanying western blot of
Figure 7C also confirmed that the UPF1 knockdown was
effective (Figure 7C, lane 5) and that the exogenously ex-
pressed RNAiR UPF1 proteins were detected (lanes 6 and
7) in the cells expressing -globin Ter 39. These results es-
tablish that the region of UPF1 HD that we have identified
as being involved in a phosphorylation-independent inter-
action with SMG6 is essential for NMD in human cells.
DISCUSSION
SMG6 is an essential component of the NMD apparatus
in mammalian cells and we have sought to further delineate
the molecular mechanisms surrounding the regulation of its
endonucleolytic activity in the NMD pathway. To examine
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what is required for SMG6 to induce degradation uncou-
pled from what is needed for its recruitment to the mRNA,
we established an SMG6-TFA in HeLa cells. The combina-
tion of the TFA with knockdowns of other NMD factors
allowed us to identify NMD factors required for SMG6-
mediated decay in NMD.
Contrary to a previous study (57) but in keeping with a
recent study (17), we found that tethered SMG6 resulted
in strongly reduced reporter mRNA levels, bypassing the
need for a PTC (Figure 1B and Supplementary Figure S2).
We also examined the SMG6 14-3-3-like domain and the
EBMs, both of which have been implicated in the recruit-
ment of SMG6 to mRNPs. We reasoned that if these parts
of SMG6 are solely involved in the function of recruit-
ing SMG6 to NMD-targeted mRNPs, then their function
should be bypassed by the MS2-mediated tethering and
thus no longer critical for SMG6 activity in the TFA. This
is what we observed with the SMG6-14-3-3 mutant, which
was fully active in the TFA albeit its association with P-
UPF1 was strongly diminished (Figure 1D and Supplemen-
tary Figure S4A). On the contrary, mutations made to the
EBMs in the N-terminus of SMG6 compromised the activ-
ity of SMG6 in the TFA (Figure 1D), suggesting that in ad-
dition to its role in recruitment of SMG6 to the mRNP, the
EBM also seems to play a role in activating SMG6 activ-
ity. It was proposed that SMG6 gained its target specificity
by binding to the EJC via these conserved motifs, yet they
are lacking from D. melanogaster SMG6 (20,58), where it
has been demonstrated that the components of the EJC are
not essential for NMDand that PTC definition occurs inde-
pendently of exon boundaries (59). Furthermore, the EBMs
most likely do not contribute to the SMG6 recruitment to
mRNPs in the EJC-independent mode of NMD in mam-
malian cells (27) but the involvement of non-canonical EJC
(60,61) in the EJC-independent NMDmode cannot be for-
mally excluded. Since our data also show that SMG6 can-
not bind RNA itself (Figure 6D), it seems highly plausible
that P-UPF1 recruits SMG6 via its 14-3-3-like domain to
the mRNP.
When brought to the target RNA, SMG6 is known to in-
duce endonucleolytic cleavage (24,25) and in line with this,
we were able to show that the PIN domain of SMG6 is ab-
solutely essential for the ability of tethered SMG6 to in-
duce reduction of reporter mRNA levels, yet we also dis-
covered that the PIN domain on its own is not sufficient in
human cells (Figure 1E). This is contrary to what has been
reported for SMG6 in D. melanogaster, where experiments
performed in S2 cells showed that tethering of the SMG6
PIN domain could degrade reporter mRNA as well if not
even slightly better than full-length SMG6 (21). Nonethe-
less, we deduced that in human cells an intact SMG6 pro-
tein is required for its activity in vivo, which already strongly
hinted at other parts of SMG6 being important and most
likely other factors being essential for SMG6-mediated de-
cay. This is in line with a recent study that showed in SMG6
lacking cells that all parts of SMG6 were required to res-
cue NMD of classical reporter mRNAs (TCR- and -
globin +/− PTCs) and that the N-terminus of SMG6 can
co-IP with most other NMD factors (20). Such a conclu-
sion might also explain why we (Supplementary Figure S7)
and other studies observe such poor SMG6 endonuclease
activity in vitro where other factors are simply lacking for
efficient enzymatic activities (21,24,25).
To identify which other NMD factors are needed for
SMG6 function, we looked to see if UPF1, UPF2, SMG1,
SMG5 and SMG7were needed for SMG6 activity in our as-
says. Indeed, we could specifically show that the presence of
both SMG1 and UPF1 was needed for efficient SMG6 ac-
tivity in the TFAs, even in the case of the SMG6-4-3-3 and
EBM mutants (Figure 2 and Supplementary Figure S3 A,
B, D, F and H). Intriguingly, the SMG6 EBM mutant also
had no activity in cells lacking UPF2 or UPF3B (Figure 2D
and Supplementary Figure S3C, F,G andH). Thus, it seems
that UPF2 and UPF3B become essential for SMG6 activa-
tion when SMG6 cannot associate with the EJC, consistent
with our previous observation that the EJC-independent
NMD mode was more sensitive to depletion of UPF2 and
UPF3B than EJC-enhanced NMD (27). Additionally, we
found that while the EBM mutant retained its weak inter-
action to UPF1, it strongly reduced its interaction with P-
UPF1 (Supplementary Figure S4A), which may signify that
SMG6 connects to the EJC while it is being recruited by P-
UPF1, meaning that it is recruited by two means; one by
anchoring on to the EJC and the other by P-UPF1, adding
extra specificity to the SMG6 recruitment process.However,
collectively our results suggest that there is more to the role
of the EBM motifs in SMG6 than simply a means to re-
cruit SMG6 to target mRNPs and future work should try
to determine the contribution these motifs play to SMG6
activity in NMD.
The observation that SMG6 decay function requires
UPF1 and kinase-competent SMG1 immediately insinu-
ated a requirement for UPF1 phosphorylation (Figure 2B
and Supplementary Figure S5). However, and in con-
trast to recent work (17), the UPF1 T28A mutant res-
cued SMG6 tethering mediated reporter mRNA reduc-
tion in cells depleted of endogenous UPF1 as efficiently
as UPF1 WT (Figure 3C), arguing that UPF1 could ac-
tivate SMG6 through a contact different from the previ-
ously characterized interaction between the UPF1 P-T28
and the SMG6 14-3-3-like domain. Our results advocate
that thewell-documented P-UPF1-SMG6 interaction prob-
ably represents themeans to get SMG6 to the target mRNP,
a step bypassed in the TFA, while the subsequent acti-
vation of endonuclease activity of SMG6 depends on a
phosphorylation-independent interactionwithUPF1.With
regards to SMG1, it may be that its kinase activity is needed
to phosphorylate sites on another NMD factor. For exam-
ple, it is known that human and yeast UPF2 can be phos-
phorylated but the function of P-UPF2 in NMD is not yet
known (62,63). It is also very likely that SMG1 can phos-
phorylate UPF1 at various P-sites and by doing so dictates
the function of UPF1 in many aspects of NMD such as
RNA binding, enzymatic activity and recruitment of var-
ious factors beyond SMG6 and SMG5-7. Recently, it was
documented in yeast that two newly identified P-sites in
UPF1 act to promote ATP hydrolysis, NMD efficiency and
translation termination fidelity (50). Further work is needed
to delineate the roles of each individual UPF1 P-site and
their contribution to UPF1 function.
Our hypothesis of a phosphorylation-independent inter-
action betweenUPF1 and SMG6was corroborated by find-
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ing that both proteins consistently co-immunoprecipitated
each other, regardless of the mutations made in either
protein (Supplementary Figure S4). This has also been
observed in other studies but never further investigated
(18,20). Using yeast two-hybrid assays, we discovered a
phosphorylation-independent interaction between the HD
of UPF1 and SMG6 (Figure 4B) and narrowed down the
interaction point within UPF1 HD to the stalk structure
comprising AA 271-433 (Figure 4D). We were initially con-
cerned that the observed loss of interaction between the
UPF1 Stalk and SMG6 in our interaction studies was ac-
tually to do with a detrimental effect on UPF1 RNA bind-
ing but we demonstrated that the deletion of the stalk and
hence sub-domain 1B did not abolish RNA binding (Fig-
ure 6B). Furthermore, UPF1 and SMG6 could still co-IP
even in the presence of RNase A (Supplementary Figure
S4), and UPF1 lacking 1C, which hindered RNA binding
(Figure 6C), still interacted with SMG6 (Figures 4D and
5D), further indicating that the stalk/1B structure of the
UPF1 HD directly interacts with SMG6.
In mapping AA 271-433 of UPF1 isoform 2 to bind to
SMG6, we realized that this fragment covers the only al-
teration between human UPF1 isoform 2 and isoform 1: at
amino acid position 353, the less abundant isoform 1 has
an insertion of 11 amino acids. Since the alternative splic-
ing event generating the two isoforms appears to be highly
conserved and because we could detect the mRNA of both
isoforms in our cells, we examined the tantalizing possibil-
ity that UPF1 isoform 1 might have a different affinity for
binding to SMG6. However, we could not detect any differ-
ence between the two human UPF1 isoforms with regard
to binding SMG6, being needed for SMG6 activity (Sup-
plementary Figure S8), or even for its involvement inNMD.
However, it still does beg the question as to why the cell pro-
duces twoUPF1 isoforms, differing only by 11 amino acids.
Finally, UPF1 Stalk could not rescue tethered SMG6-
mediated RNA degradation in cells lacking endogenous
UPF1, validating that this region of UPF1 is essential for
SMG6 activity (Figure 7A). In addition, we could demon-
strate that the UPF1 stalk structure is required for NMD
(Figure 7B and C).
With regard to which parts of SMG6 interact withUPF1,
our results hint toward the N-terminal part of SMG6
(AA 1-576), because neither the SMG6 814-1419 con-
struct nor the C-terminal PIN domain or the 14-3-3-like
domain interacted with UPF1 in yeast two-hybrid assays
(Supplementary Figure S6D and E). This is in line with
a previous study showing that removal of the SMG6 N-
terminal 576 AA abolished co-IPs between SMG6 and
UPF1 (20). Unfortunately, our constructs containing the
unstructured N-terminal region of SMG6 did not express
in yeast, which prevented further mapping of this region.
Notably, it has been suggested that the interacting com-
plexes inNMDcontain disordered protein components and
that their flexibility plays a crucial role in the formation of
long-reaching protein–protein interactions. Within the dis-
ordered N-terminus of SMG6, eight protein–protein inter-
action sites have been predicted, one of which maps to the
EBM1 at the very N-terminus (64). From the seven remain-
ing sites, one site spanning AA 401-424 is a conserved site
that could potentially be the site needed for an interaction
with the UPF1 HD.
In further assessing the yeast two-hybrid data, we consis-
tently observed that the presence of the CH domain weak-
ened the interaction of UPF1 with SMG6 in the yeast two-
hybrid assays, while the interaction between the UPF1 HD
and SMG6 appeared consistently stronger when the HD
still had its SQ domain present (Figure 4). Despite the
data being predominately qualitative, these observations in-
dicated that the presence of the CH domain inhibits and
the presence of the SQ domain enhances the interaction
of SMG6 with the UPF1 HD. Therefore, when we sought
to confirm the interaction between UPF1 stalk region and
SMG6 in vitro by pull-down experiments, we also tested
truncations of the SQ domain. While deletion of the stalk
region reduced UPF1 binding to SMG6 only partially, ad-
ditional removal of the proximal part of the SQ domain al-
most completely abolished the interaction between UPF1
and SMG6 (Figure 5D). Therefore, we can show along with
Chakrabarti et al. that the SQ domain makes a significant
contribution to the interaction between UPF1 stalk and
SMG6 (48). The CH and SQ domains of UPF1 engage in
intramolecular interactions with the HD to suppress its en-
zymatic activities and only when UPF2 binds to the CH
domain and another unidentified factor binds to the SQ do-
main, this repression is lifted andUPF1 enzymatic activities
are induced (30,53). It was further shown that when UPF2
binds to UPF1, triggering ATPase and helicase activities,
this is accompanied by a switch from an RNA clamping
mode to a more relaxed UPF1 grip on the RNA (30) and
this is keeping with the fact that we observed in vitro that
UPF1 F192E, which inhibits the allosteric inhibition from
the CHdomain toRecA2 (30,65), and P-UPF1 both had re-
duced affinity for RNA compared to wild-type UPF1 (data
not shown). Based on our observations, we speculated that
SMG6 may also be involved in this intricate regulation of
UPF1 enzymatic activities and/or RNA binding affinities.
The observed inhibitory effect of the CH domain on the in-
teraction between SMG6 and UPF1 HD in the yeast two-
hybrid assays could be explained by the absence of UPF2
in the yeast nucleus, which would result in the UPF1 con-
formation in which the CH domain is repressing the HD
domain. In NMD, UPF2 binding probably precedes the in-
teraction between UPF1 and SMG6. Yet, the interaction
between UPF1 and SMG6 also involves the proximal part
of the SQ domain. It is very plausible that the unidentified
factor that specifically binds to the SQ domain to abolish
the intramolecular interactions repressing the HD activities
may be SMG6. This possibility is in line with the fact that
SMG6 is involved in the UPF1 dissociation from mRNA
(18), which already suggested that SMG6may have a role to
play in ATP binding, ATPase and/or RNA binding activ-
ity of UPF1. Moreover, UPF1 ATPase activity is required
for UPF1 dissociation from mRNA but there has been no
analysis performed to date that would implicate the involve-
ment of SMG6. Structural studies and further biochemical
studies beyond the scope of this investigation will have to
address this exciting possibility.
UPF1, SMG1 and SMG6 are the only enzymes spe-
cific to the NMD pathway and recent studies have started
to give insight into how the enzymatic activities of UPF1
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(30,46,51–53) and SMG1 (14,34,66) are managed in the
NMDpathway.Here, we have been able to show that SMG6
activity is also under regulation by additional proteins. The
future of trying to understand the complex regulatory dy-
namic between the three enzymes may not only be impor-
tant in trying to understand the role of these proteins in
NMD but also in other cellular processes where these three
enzymes have been implicated to also function, such as in
DNA replication, telomere metabolism and genome main-
tenance pathways (67,68).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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